Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus OSMOVIST 240.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus OSMOVIST 240.
CHOLOGRAFIN MEGLUMINE vs OSMOVIST 240
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholografin meglumine is an iodinated contrast agent that opacifies the biliary tract. It is actively taken up by hepatocytes and excreted into the bile, allowing radiographic visualization of the bile ducts and gallbladder.
Nonionic iodinated contrast medium that attenuates X-rays is excreted unchanged in urine; increases density of blood vessels and tissues to enhance radiological visualization.
Intravenous: 20 mL (10.3 g) of a 52% solution (meglumine salt) administered by slow IV injection over 3-5 minutes; repeated once after 10-15 minutes if visualization is inadequate, not to exceed 40 mL total.
Intravenous bolus injection: 0.5 mL/kg to 1 mL/kg of Osnovist 240 (240 mg iodine/mL) for CT enhancement, up to a maximum of 150 mL per dose.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic function, reflecting rapid biliary excretion; prolonged in hepatic impairment.
Terminal elimination half-life approximately 2 hours (range 1.5–4 hours) in patients with normal renal function; prolonged in renal impairment proportional to creatinine clearance.
Primarily hepatic excretion via bile into feces; renal excretion accounts for <1% of the dose in patients with normal hepatic function.
Primarily renal (glomerular filtration); >95% of administered dose excreted unchanged in urine within 24 hours. Negligible biliary/fecal elimination (<5%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent